Global Opioid Use Disorder Market Size Study & Forecast, by Drug (Naltrexone, Buprenorphine, Methadone) by Route of Administration and Distribution Channel and Regional Forecasts 2025-2035

Description

The Global Opioid Use Disorder Market is valued at approximately USD 5.28 trillion in 2024 and is anticipated to grow with a CAGR of more than 11.70% over the forecast period 2025-2035. Opioid Use Disorder (OUD) represents one of the most complex public health challenges worldwide, prompting healthcare systems to deploy evidence-based medications, advanced intervention protocols, and digitally augmented treatment pathways. OUD therapy involves pharmacological and behavioral approaches intended to reduce cravings, prevent relapse, and restore stability in patients' lives-while simultaneously strengthening community-level safeguards against opioid misuse. The rapid escalation of opioid dependency rates, alongside intensified healthcare awareness campaigns and expanded coverage for medically assisted treatment, continues to influence the strong growth trajectory of the global OUD treatment market.

The rising prevalence of opioid misuse, coupled with increasing overdose fatalities and chronic reliance on prescription pain medication, has significantly amplified the need for comprehensive OUD treatment solutions. These medications-particularly buprenorphine, methadone, and naltrexone-play a crucial role in stabilizing neurochemical pathways disrupted by prolonged opioid exposure. As governments worldwide introduce more rigorous harm-reduction frameworks, expand rehabilitation infrastructure, and mandate insurance coverage for medication-assisted therapies, the demand for long-term OUD treatments continues to intensify. However, challenges such as limited accessibility in rural regions, clinician shortages, stigmatization, and regulatory restrictions around controlled substances may inhibit faster adoption across developing countries throughout the forecast period.

The detailed segments and sub-segments included in the report are:

By Drug:

Naltrexone
Buprenorphine
Methadone

By Route of Administration:

Oral
Parenteral
Others

By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

By Region:

North America

U.S.
Canada

Europe

UK
Germany
France
Spain
Italy
ROE

Asia Pacific

China
India
Japan
Australia
South Korea
RoAPAC

Latin America

Brazil
Mexico

Middle East & Africa

UAE
Saudi Arabia
South Africa
Rest of Middle East & Africa

Buprenorphine is expected to dominate the market landscape owing to its favorable safety profile, partial agonist characteristics, and broad adoption in outpatient settings. As treatment providers increasingly shift toward regimens that can be administered in community clinics, telemedicine frameworks, and home-based care environments, buprenorphine has emerged as the most adaptable pharmacotherapy. Its capacity to stabilize patients without inducing excessive sedation or euphoria has driven its widespread use across early intervention programs. Although methadone remains a cornerstone therapy-particularly in high-dependency cases-buprenorphine continues to benefit from regulatory flexibility and broader prescriber eligibility, positioning it as the leading market driver.

Methadone currently leads the global market in terms of revenue contribution, largely attributed to its entrenched use in long-term rehabilitation programs and structured opioid treatment centers. Its powerful full-agonist mechanism delivers strong withdrawal suppression, making it indispensable for severe or chronic dependency cases. Meanwhile, naltrexone has shown significant promise in relapse prevention, particularly among patients who seek non-opioid-based treatment options. While methadone retains dominance due to large patient volumes and established treatment protocols, buprenorphine is projected to grow at the fastest pace owing to its accessibility, patient preference, and integration into digital prescribing ecosystems.

The key regions considered for the Global Opioid Use Disorder Market include Asia Pacific, North America, Europe, Latin America, and the Middle East & Africa. North America dominated the market in 2025, supported by robust healthcare infrastructure, high diagnostic penetration, wide availability of opioid treatment programs, and extensive harm-reduction initiatives implemented through federal and state-level policies. Europe follows with strong adoption of medication-assisted treatment frameworks and stringent public-health oversight. Asia Pacific, however, is expected to emerge as the fastest-growing region over the forecast period due to rising awareness of substance misuse, increasing investments in treatment facilities, government-backed rehabilitation campaigns, and an expanding patient pool across India, China, and Southeast Asia.

Major market players included in this report are:

Indivior PLC
Alkermes Plc
Hikma Pharmaceuticals
Teva Pharmaceutical Industries
Pfizer Inc.
Mallinckrodt Pharmaceuticals
Camurus AB
Apotex Inc.
Sun Pharmaceutical Industries
Viatris Inc.
Emergent BioSolutions
Cipla Ltd
Novartis AG
Dr. Reddy's Laboratories
Amneal Pharmaceuticals

Global Opioid Use Disorder Market Report Scope:

Historical Data - 2023, 2024
Base Year for Estimation - 2024
Forecast period - 2025-2035
Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
Customization Scope - Free report customization (equivalent to up to 8 analysts' working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values for the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within the countries involved in the study. The report also provides detailed information about crucial aspects, such as driving factors and challenges, which will define the future growth of the market. Additionally, it incorporates potential opportunities in micro-markets for stakeholders to invest, along with a detailed analysis of the competitive landscape and product offerings of key players. The detailed segments and sub-segments of the market are explained above.

Key Takeaways:

Market Estimates & Forecast for 10 years from 2025 to 2035.
Annualized revenues and regional-level analysis for each market segment.
Detailed analysis of the geographical landscape with country-level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of the competitive structure of the market.
Demand-side and supply-side analysis of the market.

Chapter 1. Global Opioid Use Disorder Market Report Scope & Methodology

1.1. Research Objective
1.2. Research Methodology
- 1.2.1. Forecast Model
- 1.2.2. Desk Research
- 1.2.3. Top Down and Bottom-Up Approach
1.3. Research Attributes
1.4. Scope of the Study
- 1.4.1. Market Definition
- 1.4.2. Market Segmentation
1.5. Research Assumption
- 1.5.1. Inclusion & Exclusion
- 1.5.2. Limitations
- 1.5.3. Years Considered for the Study

Chapter 2. Executive Summary

2.1. CEO/CXO Standpoint
2.2. Strategic Insights
2.3. ESG Analysis
2.4. key Findings

Chapter 3. Global Opioid Use Disorder Market Forces Analysis

3.1. Market Forces Shaping The Global Opioid Use Disorder Market (2024-2035)
3.2. Drivers
- 3.2.1. rapid escalation of opioid dependency rates
- 3.2.2. Increasing Healthcare awareness
3.3. Restraints
- 3.3.1. rising prevalence of opioid misuse
3.4. Opportunities
- 3.4.1. Growing Awareness About Hormonal Deficiencies

Chapter 4. Global Opioid Use Disorder Industry Analysis

4.1. Porter's 5 Forces Model
- 4.1.1. Bargaining Power of Buyer
- 4.1.2. Bargaining Power of Supplier
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
4.2. Porter's 5 Force Forecast Model (2024-2035)
4.3. PESTEL Analysis
- 4.3.1. Political
- 4.3.2. Economical
- 4.3.3. Social
- 4.3.4. Technological
- 4.3.5. Environmental
- 4.3.6. Legal
4.4. Top Investment Opportunities
4.5. Top Winning Strategies (2025)
4.6. Market Share Analysis (2024-2025)
4.7. Global Pricing Analysis And Trends 2025
4.8. Analyst Recommendation & Conclusion

Chapter 5. Global Opioid Use Disorder Market Size & Forecasts by Drug 2025-2035

5.1. Market Overview
5.2. Global Opioid Use Disorder Market Performance - Potential Analysis (2025)
5.3. Naltrexone
- 5.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 5.3.2. Market size analysis, by region, 2025-2035
5.4. Buprenorphine
- 5.4.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 5.4.2. Market size analysis, by region, 2025-2035
5.5. Methadone
- 5.5.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 5.5.2. Market size analysis, by region, 2025-2035

Chapter 6. Global Opioid Use Disorder Market Size & Forecasts by Route of Administration 2025-2035

6.1. Market Overview
6.2. Global Opioid Use Disorder Market Performance - Potential Analysis (2025)
6.3. Oral
- 6.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 6.3.2. Market size analysis, by region, 2025-2035
6.4. Parenteral
- 6.4.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 6.4.2. Market size analysis, by region, 2025-2035
6.5. Others
- 6.5.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 6.5.2. Market size analysis, by region, 2025-2035

Chapter 7. Global Opioid Use Disorder Market Size & Forecasts by Distribution channel 2025-2035

7.1. Market Overview
7.2. Global Opioid Use Disorder Market Performance - Potential Analysis (2025)
7.3. Hospital Pharmacies
- 7.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 7.3.2. Market size analysis, by region, 2025-2035
7.4. Retail Pharmacies
- 7.4.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 7.4.2. Market size analysis, by region, 2025-2035
7.5. Online Pharmacies
- 7.5.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 7.5.2. Market size analysis, by region, 2025-2035

Chapter 8. Global Opioid Use Disorder Market Size & Forecasts by Region 2025-2035

8.1. Growth Opioid Use Disorder Market, Regional Market Snapshot
8.2. Top Leading & Emerging Countries
8.3. North America Opioid Use Disorder Market
- 8.3.1. U.S. Opioid Use Disorder Market
  - 8.3.1.1. Drug breakdown size & forecasts, 2025-2035
  - 8.3.1.2. Route of Administration breakdown size & forecasts, 2025-2035
  - 8.3.1.3. Distribution channel breakdown size & forecasts, 2025-2035
- 8.3.2. Canada Opioid Use Disorder Market
  - 8.3.2.1. Drug breakdown size & forecasts, 2025-2035
  - 8.3.2.2. Route of Administration breakdown size & forecasts, 2025-2035
  - 8.3.2.3. Distribution channel breakdown size & forecasts, 2025-2035
8.4. Europe Opioid Use Disorder Market
- 8.4.1. UK Opioid Use Disorder Market
  - 8.4.1.1. Drug breakdown size & forecasts, 2025-2035
  - 8.4.1.2. Route of Administration breakdown size & forecasts, 2025-2035
  - 8.4.1.3. Distribution channel breakdown size & forecasts, 2025-2035
- 8.4.2. Germany Opioid Use Disorder Market
  - 8.4.2.1. Drug breakdown size & forecasts, 2025-2035
  - 8.4.2.2. Route of Administration breakdown size & forecasts, 2025-2035
  - 8.4.2.3. Distribution channel breakdown size & forecasts, 2025-2035
- 8.4.3. France Opioid Use Disorder Market
  - 8.4.3.1. Drug breakdown size & forecasts, 2025-2035
  - 8.4.3.2. Route of Administration breakdown size & forecasts, 2025-2035
  - 8.4.3.3. Distribution channel breakdown size & forecasts, 2025-2035
- 8.4.4. Spain Opioid Use Disorder Market
  - 8.4.4.1. Drug breakdown size & forecasts, 2025-2035
  - 8.4.4.2. Route of Administration breakdown size & forecasts, 2025-2035
  - 8.4.4.3. Distribution channel breakdown size & forecasts, 2025-2035
- 8.4.5. Italy Opioid Use Disorder Market
  - 8.4.5.1. Drug breakdown size & forecasts, 2025-2035
  - 8.4.5.2. Route of Administration breakdown size & forecasts, 2025-2035
  - 8.4.5.3. Distribution channel breakdown size & forecasts, 2025-2035
- 8.4.6. Rest of Europe Opioid Use Disorder Market
  - 8.4.6.1. Drug breakdown size & forecasts, 2025-2035
  - 8.4.6.2. Route of Administration breakdown size & forecasts, 2025-2035
  - 8.4.6.3. Distribution channel breakdown size & forecasts, 2025-2035
8.5. Asia Pacific Opioid Use Disorder Market
- 8.5.1. China Opioid Use Disorder Market
  - 8.5.1.1. Drug breakdown size & forecasts, 2025-2035
  - 8.5.1.2. Route of Administration breakdown size & forecasts, 2025-2035
  - 8.5.1.3. Distribution channel breakdown size & forecasts, 2025-2035
- 8.5.2. India Opioid Use Disorder Market
  - 8.5.2.1. Drug breakdown size & forecasts, 2025-2035
  - 8.5.2.2. Route of Administration breakdown size & forecasts, 2025-2035
  - 8.5.2.3. Distribution channel breakdown size & forecasts, 2025-2035
- 8.5.3. Japan Opioid Use Disorder Market
  - 8.5.3.1. Drug breakdown size & forecasts, 2025-2035
  - 8.5.3.2. Route of Administration breakdown size & forecasts, 2025-2035
  - 8.5.3.3. Distribution channel breakdown size & forecasts, 2025-2035
- 8.5.4. Australia Opioid Use Disorder Market
  - 8.5.4.1. Drug breakdown size & forecasts, 2025-2035
  - 8.5.4.2. Route of Administration breakdown size & forecasts, 2025-2035
  - 8.5.4.3. Distribution channel breakdown size & forecasts, 2025-2035
- 8.5.5. South Korea Opioid Use Disorder Market
  - 8.5.5.1. Drug breakdown size & forecasts, 2025-2035
  - 8.5.5.2. Route of Administration breakdown size & forecasts, 2025-2035
  - 8.5.5.3. Distribution channel breakdown size & forecasts, 2025-2035
- 8.5.6. Rest of APAC Opioid Use Disorder Market
  - 8.5.6.1. Drug breakdown size & forecasts, 2025-2035
  - 8.5.6.2. Route of Administration breakdown size & forecasts, 2025-2035
  - 8.5.6.3. Distribution channel breakdown size & forecasts, 2025-2035
8.6. Latin America Opioid Use Disorder Market
- 8.6.1. Brazil Opioid Use Disorder Market
  - 8.6.1.1. Drug breakdown size & forecasts, 2025-2035
  - 8.6.1.2. Route of Administration breakdown size & forecasts, 2025-2035
  - 8.6.1.3. Distribution channel breakdown size & forecasts, 2025-2035
- 8.6.2. Mexico Opioid Use Disorder Market
  - 8.6.2.1. Drug breakdown size & forecasts, 2025-2035
  - 8.6.2.2. Route of Administration breakdown size & forecasts, 2025-2035
  - 8.6.2.3. Distribution channel breakdown size & forecasts, 2025-2035
8.7. Middle East and Africa Opioid Use Disorder Market
- 8.7.1. UAE Opioid Use Disorder Market
  - 8.7.1.1. Drug breakdown size & forecasts, 2025-2035
  - 8.7.1.2. Route of Administration breakdown size & forecasts, 2025-2035
  - 8.7.1.3. Distribution channel breakdown size & forecasts, 2025-2035
- 8.7.2. Saudi Arabia (KSA) Opioid Use Disorder Market
  - 8.7.2.1. Drug breakdown size & forecasts, 2025-2035
  - 8.7.2.2. Route of Administration breakdown size & forecasts, 2025-2035
  - 8.7.2.3. Distribution channel breakdown size & forecasts, 2025-2035
- 8.7.3. South Africa Opioid Use Disorder Market
  - 8.7.3.1. Drug breakdown size & forecasts, 2025-2035
  - 8.7.3.2. Route of Administration breakdown size & forecasts, 2025-2035
  - 8.7.3.3. Distribution channel breakdown size & forecasts, 2025-2035

Chapter 9. Competitive Intelligence

9.1. Top Market Strategies
9.2. Indivior PLC
- 9.2.1. Company Overview
- 9.2.2. Key Executives
- 9.2.3. Company Snapshot
- 9.2.4. Financial Performance (Subject to Data Availability)
- 9.2.5. Product/Services Port
- 9.2.6. Recent Development
- 9.2.7. Market Strategies
- 9.2.8. SWOT Analysis
9.3. Alkermes Plc
9.4. Hikma Pharmaceuticals
9.5. Teva Pharmaceutical Industries
9.6. Pfizer Inc.
9.7. Mallinckrodt Pharmaceuticals
9.8. Camurus AB
9.9. Apotex Inc.
9.10. Sun Pharmaceutical Industries
9.11. Viatris Inc.
9.12. Emergent BioSolutions
9.13. Cipla Ltd
9.14. Novartis AG
9.15. Dr. Reddy's Laboratories
9.16. Amneal Pharmaceuticals